EMA’s committee for human medicines (CHMP) has approved an additional manufacturing site for the production of COVID-19 Vaccine Janssen, the COVID-19 vaccine developed by Janssen-Cilag International NV.
The site, located in Anagni, Italy, is operated by Catalent Anagni SRL. The site will perform finished product manufacturing.
The site is expected to support the continued supply of COVID-19 Vaccine Janssen in the European Union.
This recommendation does not require a European Commission decision and the site can become operational immediately.
Notes
- This press release, together with all related documents, is available on the Agency’s website.
- More information on the work of the European Medicines Agency can be found on its website: www.ema.europa.eu
